You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR ONDANSETRON HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for ONDANSETRON HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00124787 ↗ A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis Completed Canadian Association of Emergency Physicians Phase 4 2005-04-01 Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
OTC NCT00124787 ↗ A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis Completed St. Justine's Hospital Phase 4 2005-04-01 Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
OTC NCT01691690 ↗ Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed Nationwide Children's Hospital Phase 2 2012-10-01 Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for ONDANSETRON HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000289 ↗ Role of Metabolites in Nicotine Dependence (3) - 6 Completed University of Minnesota Phase 2 1998-05-01 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000289 ↗ Role of Metabolites in Nicotine Dependence (3) - 6 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1998-05-01 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000289 ↗ Role of Metabolites in Nicotine Dependence (3) - 6 Completed National Institute on Drug Abuse (NIDA) Phase 2 1998-05-01 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000443 ↗ Ondansetron Treatment for Alcoholism Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the treatment of alcohol dependent patients; b) investigate whether early versus late onset alcoholism predicts treatment outcome; and c) determine whether the early and late onset groups respond differently to treatment. Individuals will be "typed" into early onset and late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient treatment program.
NCT00003817 ↗ Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy Completed National Cancer Institute (NCI) Phase 2 1999-10-01 RATIONALE: Pressure or nerve stimulation applied to an acupuncture point on the inside of the wrist may help control nausea and vomiting during chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of acupressure and acustimulation wrist bands in treating nausea and vomiting in patients undergoing chemotherapy for cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ONDANSETRON HYDROCHLORIDE

Condition Name

Condition Name for ONDANSETRON HYDROCHLORIDE
Intervention Trials
Postoperative Nausea and Vomiting 59
Nausea 42
Vomiting 38
Postoperative Pain 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ONDANSETRON HYDROCHLORIDE
Intervention Trials
Vomiting 210
Nausea 163
Postoperative Nausea and Vomiting 104
Pain, Postoperative 66
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ONDANSETRON HYDROCHLORIDE

Trials by Country

Trials by Country for ONDANSETRON HYDROCHLORIDE
Location Trials
United States 551
Canada 90
Egypt 41
Italy 39
Germany 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ONDANSETRON HYDROCHLORIDE
Location Trials
Texas 55
New York 37
California 35
North Carolina 27
Illinois 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ONDANSETRON HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for ONDANSETRON HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 164
Phase 3 87
Phase 2/Phase 3 17
[disabled in preview] 124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ONDANSETRON HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 349
Recruiting 78
Unknown status 58
[disabled in preview] 90
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ONDANSETRON HYDROCHLORIDE

Sponsor Name

Sponsor Name for ONDANSETRON HYDROCHLORIDE
Sponsor Trials
Merck Sharp & Dohme Corp. 30
GlaxoSmithKline 14
M.D. Anderson Cancer Center 13
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ONDANSETRON HYDROCHLORIDE
Sponsor Trials
Other 738
Industry 142
NIH 37
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.